[{"id":"c39317e9-2ffe-4fe5-b487-781ec7511b8d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02923180","created_at":"2021-01-18T14:21:11.868Z","updated_at":"2024-07-02T16:34:25.763Z","phase":"Phase 2","brief_title":"Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer","source_id_and_acronym":"NCT02923180","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" AR • PD-1 • LAG3 • CD276 • HAVCR2 • TNFRSF9 • LAMP1","pipe":" | ","alterations":" CD276 expression • LAG3 expression • HAVCR2 expression • LAMP1 expression","tags":["AR • PD-1 • LAG3 • CD276 • HAVCR2 • TNFRSF9 • LAMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression • LAG3 expression • HAVCR2 expression • LAMP1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e enoblituzumab (MGA271)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 02/14/2017","start_date":" 02/14/2017","primary_txt":" Primary completion: 08/11/2020","primary_completion_date":" 08/11/2020","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-14"},{"id":"8d7085c4-b70c-4d81-8155-40e3a80cc9f5","acronym":"HEAT","url":"https://clinicaltrials.gov/study/NCT06014255","created_at":"2023-08-28T14:08:37.514Z","updated_at":"2024-07-02T16:34:27.119Z","phase":"Phase 2","brief_title":"Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer","source_id_and_acronym":"NCT06014255 - HEAT","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PD-1 • LAG3 • CD276 • TNFRSF9 • LAMP1","pipe":" | ","alterations":" PD-L1 expression • LAMP1 expression","tags":["PD-1 • LAG3 • CD276 • TNFRSF9 • LAMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • LAMP1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e enoblituzumab (MGA271)"],"overall_status":"Recruiting","enrollment":" Enrollment 219","initiation":"Initiation: 02/16/2024","start_date":" 02/16/2024","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2024-06-11"},{"id":"4bdc6995-4092-4a59-a2d4-49ba4544cf90","acronym":"","url":"https://clinicaltrials.gov/study/NCT05338580","created_at":"2022-04-21T15:55:23.863Z","updated_at":"2024-07-02T16:35:09.726Z","phase":"Phase 2","brief_title":"Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT05338580","lead_sponsor":"TJ Biopharma Co., Ltd.","biomarkers":" PD-L1 • CD276 • CD73","pipe":" | ","alterations":" PD-L1 expression • CD73 expression","tags":["PD-L1 • CD276 • CD73"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CD73 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • enoblituzumab (MGA271)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/31/2023","start_date":" 12/31/2023","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2024-04-15"},{"id":"00c35bc1-188e-4099-b934-09f9bbb72f40","acronym":"","url":"https://clinicaltrials.gov/study/NCT01391143","created_at":"2021-01-18T05:42:37.598Z","updated_at":"2024-07-02T16:36:17.398Z","phase":"Phase 1","brief_title":"Safety Study of MGA271 in Refractory Cancer","source_id_and_acronym":"NCT01391143","lead_sponsor":"MacroGenics","biomarkers":" CD276","pipe":" | ","alterations":" CD276 overexpression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e enoblituzumab (MGA271)"],"overall_status":"Completed","enrollment":" Enrollment 179","initiation":"Initiation: 07/01/2011","start_date":" 07/01/2011","primary_txt":" Primary completion: 04/18/2019","primary_completion_date":" 04/18/2019","study_txt":" Completion: 04/18/2019","study_completion_date":" 04/18/2019","last_update_posted":"2022-02-08"},{"id":"062d5143-0a78-494c-8bc5-54eadaa88e52","acronym":"","url":"https://clinicaltrials.gov/study/NCT02381314","created_at":"2021-01-18T11:20:48.335Z","updated_at":"2024-07-02T16:36:17.470Z","phase":"Phase 1","brief_title":"Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer","source_id_and_acronym":"NCT02381314","lead_sponsor":"MacroGenics","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • enoblituzumab (MGA271)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 03/26/2015","start_date":" 03/26/2015","primary_txt":" Primary completion: 11/09/2017","primary_completion_date":" 11/09/2017","study_txt":" Completion: 09/26/2018","study_completion_date":" 09/26/2018","last_update_posted":"2022-02-08"},{"id":"7aab657d-ec00-44a4-a26a-a330dd1b6981","acronym":"","url":"https://clinicaltrials.gov/study/NCT04129320","created_at":"2021-01-18T20:10:22.793Z","updated_at":"2024-07-02T16:36:17.436Z","phase":"Phase 2/3","brief_title":"Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck","source_id_and_acronym":"NCT04129320","lead_sponsor":"MacroGenics","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • tebotelimab (MGD013) • enoblituzumab (MGA271)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2019","start_date":" 10/01/2019","primary_txt":" Primary completion: 10/01/2020","primary_completion_date":" 10/01/2020","study_txt":" Completion: 10/01/2022","study_completion_date":" 10/01/2022","last_update_posted":"2022-02-08"},{"id":"e895d13d-aaf1-4c85-81b2-e4cc448e1e94","acronym":"","url":"https://clinicaltrials.gov/study/NCT02982941","created_at":"2021-01-18T14:40:26.657Z","updated_at":"2024-07-02T16:36:17.394Z","phase":"Phase 1","brief_title":"Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors","source_id_and_acronym":"NCT02982941","lead_sponsor":"MacroGenics","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e enoblituzumab (MGA271)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 05/22/2019","primary_completion_date":" 05/22/2019","study_txt":" Completion: 05/22/2019","study_completion_date":" 05/22/2019","last_update_posted":"2022-02-08"},{"id":"6dbe45e6-1246-42ed-ac2a-33333a3bb5df","acronym":"","url":"https://clinicaltrials.gov/study/NCT02475213","created_at":"2021-01-18T11:55:04.422Z","updated_at":"2024-07-02T16:36:23.857Z","phase":"Phase 1","brief_title":"Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer","source_id_and_acronym":"NCT02475213","lead_sponsor":"MacroGenics","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • Zynyz (retifanlimab-dlwr) • enoblituzumab (MGA271)"],"overall_status":"Completed","enrollment":" Enrollment 145","initiation":"Initiation: 07/01/2015","start_date":" 07/01/2015","primary_txt":" Primary completion: 08/18/2021","primary_completion_date":" 08/18/2021","study_txt":" Completion: 08/18/2021","study_completion_date":" 08/18/2021","last_update_posted":"2021-09-28"}]